8-K: Hempacco Co. Faces Nasdaq Delisting After Failing to Meet Listing Requirements

Hempacco Co. has received notice from Nasdaq that its securities will be delisted due to non-compliance with listing rules regarding annual shareholder meetings and filing of periodic financial reports.

Summary

• Hempacco Co. received a delisting notice from Nasdaq on September 4, 2024, due to violations of listing rules.
• The company failed to hold an annual shareholder meeting as required by Nasdaq Listing Rule 5620(a).
• Hempacco also failed to file periodic financial reports with the SEC, violating Nasdaq Listing Rule 5250(c)(1).
• Hempacco intends to request a review of the delisting decision by the Nasdaq Listing and Hearing Review Council within 15 days.
• There is no guarantee that the review will reverse the delisting decision.
• The company's stock began trading on the OTC Link Expert Market under the symbol HPCO on or about September 6, 2024.
• If the Nasdaq review is unsuccessful, Hempacco plans to apply for quotation on the OTCQB Venture Market, but there is no assurance of approval.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event (delisting from Nasdaq) and uncertainty about the company's future listing status. The sentiment is therefore very negative.

Positives

• Hempacco is taking steps to address the issues by scheduling an annual meeting and working to file delinquent reports.
• The company intends to request a review of the delisting decision by the Nasdaq Listing and Hearing Review Council.
• Hempacco has a plan to move to the OTCQB Venture Market if the Nasdaq review is unsuccessful.

Negatives

• Hempacco has failed to comply with Nasdaq listing rules regarding annual shareholder meetings and filing of periodic financial reports.
• The company's stock has been delisted from Nasdaq and is now trading on the OTC Link Expert Market.
• There is no assurance that the Nasdaq review will reverse the delisting decision.
• There is no guarantee that the company's stock will be approved for quotation on the OTCQB Venture Market.

Risks

• The company faces the risk of permanent delisting from Nasdaq if the review is unsuccessful.
• There is a risk that the company may not be able to file its delinquent reports and request the Nasdaq Listing and Hearing Council Review within the 15-day deadline.
• The company's stock may experience decreased liquidity and investor confidence due to the delisting.
• There is a risk that the company's application to the OTCQB Venture Market may not be approved.

Future Outlook

Hempacco intends to request a review of the delisting decision and, if unsuccessful, apply for quotation on the OTCQB Venture Market. There is no assurance of success in either of these actions.

Management Comments

• The Company has scheduled an annual meeting of the shareholders and is focused on filing its delinquent periodic reports as soon as possible.
• The Company therefore intends to request the Nasdaq Listing and Hearing Council Review.

Industry Context

This delisting highlights the importance of compliance with exchange listing rules, particularly for companies seeking to maintain investor confidence and access to capital markets. It is not uncommon for companies to face delisting for non-compliance, and this event underscores the need for robust corporate governance and financial reporting practices.

Comparison to Industry Standards

• Many companies listed on Nasdaq are required to maintain compliance with listing rules, including holding annual shareholder meetings and filing periodic financial reports.
• Failure to meet these requirements can lead to delisting, as seen in this case with Hempacco.
• Other companies that have faced similar delisting issues include those with financial reporting irregularities or governance failures.
• Companies like iBio, Inc. and China Xiangtai Food Co., Ltd. have faced similar delisting notices due to non-compliance with Nasdaq listing rules.

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the delisting.
• The company's reputation may be negatively impacted.
• Employees may experience uncertainty about the company's future.

Next Steps

• Hempacco will request a review of the delisting decision by the Nasdaq Listing and Hearing Review Council within 15 days.
• If the review is unsuccessful, Hempacco will apply to have its common stock quoted on the OTCQB Venture Market.

Key Dates

Keywords

delisting, Nasdaq, OTC Link, HPCO, listing rules, annual meeting, financial reports, SEC, OTCQB, review